Leerink Partners Downgrades AlloVir to Market Perform, Announces $1 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar downgraded AlloVir (NASDAQ:ALVR) from Outperform to Market Perform and set a price target of $1. This represents a significant change in the firm's outlook on AlloVir's stock performance.

December 22, 2023 | 4:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leerink Partners has downgraded AlloVir from Outperform to Market Perform and set a price target of $1, indicating a bearish outlook on the stock.
The downgrade from Outperform to Market Perform by a reputable analyst like Mani Foroohar suggests a less favorable outlook for AlloVir's stock, which could lead to a decrease in investor confidence and a potential drop in the stock price in the short term. The announcement of a $1 price target, presumably below the current trading price, further supports the likelihood of a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100